探索动脉缩的潜在转诊途径,并在爱尔兰开发一个卓越中心
Niall Leahy1,2, Max Wagener1,2, Shirjeel Shahzad1
1Cardiology Department, University Hospital Galway, Saolta Healthcare Group, Newcastle Road, Galway, H91 YR71 Ireland.
SN comprehensive clinical medicine
|March 19, 2024
概括
脏缩为失控高血压提供了一种安全有效的治疗方法,特别是对于不能耐药的患者. 需要标准化的转诊途径,以改善患者获得这种新兴疗法的机会.
科学领域:
- 心脏病学 心脏病学
- 干预性病学 干预性病学
背景情况:
- 动脉高血压是心血管疾病的主要全球风险因素.
- 尽管有可用的药物治疗方法,但高水平的不受控制的高血压仍然存在,通常是由于药物遵守不良.
- 抗性或不受控制的高血压需要替代治疗策略.
研究的目的:
- 在加尔威大学医院审查目前和正在发展的脏损的转诊途径.
- 讨论简化患者管理和建立卓越的脏缩中心的要求.
- 为解决爱尔兰对这种新兴疗法的标准化转诊结构的未满足需求.
主要方法:
- 对现有和正在发展的脏皮损伤转介途径的审查.
- 在临床环境中分析患者管理策略.
- 审查建立专业治疗中心的要求.
主要成果:
- 脏剥离已经在假控制试验中证明了降低血压的有效性和安全性.
- 对于无法耐受口服抗高血压药物的患者来说,它是一种可行的选择.
- 加尔威大学医院通过多中心试验和注册表对脏缩有经验.
结论:
- 脏缩是一种有前途的基于器件的治疗方法,用于抵抗性和不受控制的高血压.
- 标准化的转诊和管理协议对于优化患者获取和结果至关重要.
- 建立一个卓越中心将促进这种新治疗方法的广泛采用.
相关概念视频
01:18Blood and Nerve Supply to the Kidney
1.0K
The kidneys are vital organs responsible for filtering and cleaning blood, removing waste products, and regulating electrolyte levels. To perform these essential functions, they require a constant and robust blood supply.
Bloody Supply to the Kidneys:
The kidneys receive their blood supply from the renal arteries, which branch off from the abdominal aorta—the main artery supplying the abdomen and lower body. The renal arteries enter the kidneys at the hilum, a notch on the medial side of...
Bloody Supply to the Kidneys:
The kidneys receive their blood supply from the renal arteries, which branch off from the abdominal aorta—the main artery supplying the abdomen and lower body. The renal arteries enter the kidneys at the hilum, a notch on the medial side of...
1.0K
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
428
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
428